Author: Anja Schempf

Recon takes an analytical look behind select developments in healthcare

Looking into the crystal ball – What is in store for the future of gene therapy delivery?

Anja Schempf July 18, 2022

Download Here: Troubleshooting GT_Recon Strategy 2022 In the last decade, gene therapies have been a major area of development and interest. What kicked off with the approval of Spark Therapeutics’ Luxturna in 2017 has now blossomed into a robust pipeline including the approval of Zolgensma (Novartis), and a number of cutting-edge therapies in clinical trials (such as Uniqure and CSL Behring’s therapy for hemophilia or Ultragenyx’s therapy for MPS IIIA). However, while the number of gene therapies entering clinical trials has increased, so have the inevitable stumbling blocks in development.

Walmart Health: Will the fifth attempt at clinics be the charm?

Anja Schempf February 17, 2021

Eighteen months ago, WMT opened its first Walmart Health clinic attached to a supercenter in Dallas, GA. The operation combined multiple services – primary/urgent care, dentistry, behavioral health, optometry, and audiology – with WMT’s Every Day Low Price philosophy (for example, $30 total for a primary care check-up, $40 for a sick visit) in one ~11K sq. ft. site. Boosted by typical supercenter traffic (~5K visits a day is our estimate), and a scarcity of primary and dental care in the local area[1], the clinic got to 2.3K visits-per-month within

An ADC renaissance: a resurgence of antibody drug conjugates for cancer

Anja Schempf October 21, 2020

PDF: An ADC renaissance: a resurgence of antibody drug conjugates for cancer Summary: Antibody-drug conjugates (ADCs) have seen a record number of approvals in 2020. This comes after a first era of intense activity in the early 2000s followed by a period of relative quiescence from the late 2000s to mid-2010s. To understand how the nature of the ADC pipeline has changed over time, we have reviewed all 88 ADC oncology programs that have reached phase 2 development and beyond from 1997 onward. We found that, currently, the main contributor

Author: Anja Schempf

Recon takes an analytical look behind select developments in healthcare

Looking into the crystal ball – What is in store for the future of gene therapy delivery?

Walmart Health: Will the fifth attempt at clinics be the charm?

An ADC renaissance: a resurgence of antibody drug conjugates for cancer

SUBSCRIBE

Categories

Authors

Archives